-The Hindu Business Line The Government has constituted an Intellectual Property Rights (IPR) think-tank to help draft a new National IPR Policy and to advice it on issues related to intellectual property. The think-tank, headed by Justice Prabha Sridevan, will highlight anomalies in the present IPR legislations and advice the Department of Industrial Policy and Promotion (DIPP) on possible solutions, according to an official release. It will also provide views on the possible...

-The Times of India NEW DELHI: Within days of Prime Minister Narendra Modi's return from the US, the US Trade Representative (USTR) has launched a fresh offensive against India's intellectual property rights (IPR) regime, a move that may lead to the government going slow on a bilateral dialogue with Washington. On Tuesday, USTR will launch what it calls an "out-of-cycle review" (OCR) of India's IPR regime, following a report released earlier this...

-The Times of India A paragraph buried in the US-India joint statement, which talks of establishing an annual high-level Intellectual Property (IP) working group as part of the Trade Policy Forum, has made health activists across the world apprehensive that the Modi government might be bending to US pressure to change its patent laws. Several health policy experts and activists have issued statements urging India not to give in to US...

-The Hindu   No one can attack India's well-founded Intellectual Property regime as being weak merely because a drug that is claimed to be an invention fails the test of law India and its intellectual property (IP) laws have been the subject of sharp criticism recently. Now, there is talk of the government invoking emergency provisions with regard to Dasatinib, a cancer drug. The decibel level may go up several notches. Let us look...

-The Hindu Differences over intellectual property rights (IPRs) have emerged as a strong undercurrent in India's economic relations with the U.S. The attempt by the influential pharmaceutical lobby to stymie India's efforts to ensure the supply of medicines at affordable rates without violating existing treaty commitments, requires a principled response from New Delhi. At the core of the issue is what Columbia University Professor Arvind Panagariya calls "the hijacking of...